143 related articles for article (PubMed ID: 2977272)
1. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.
Ryan PG; Peeling WB
Am J Clin Oncol; 1988; 11 Suppl 2():S169-72. PubMed ID: 2977272
[TBL] [Abstract][Full Text] [Related]
2. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
3. Zoladex treatment of symptomatic prostatic carcinoma.
Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
[TBL] [Abstract][Full Text] [Related]
4. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
Peeling WB
Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
[No Abstract] [Full Text] [Related]
5. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.
Turkes AO; Peeling WB; Griffiths K
J Steroid Biochem; 1987; 27(1-3):543-9. PubMed ID: 2961938
[TBL] [Abstract][Full Text] [Related]
6. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
Kaisary AV; Tyrrell CJ; Peeling WB; Griffiths K
Br J Urol; 1991 May; 67(5):502-8. PubMed ID: 1828183
[TBL] [Abstract][Full Text] [Related]
7. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
[TBL] [Abstract][Full Text] [Related]
8. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
9. LH-RH analogue treatment for advanced prostate cancer.
Alcini E; D'Addessi A; Destito A; Grasso G
Am J Clin Oncol; 1988; 11 Suppl 2():S120-2. PubMed ID: 2977266
[TBL] [Abstract][Full Text] [Related]
10. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
[TBL] [Abstract][Full Text] [Related]
11. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
[TBL] [Abstract][Full Text] [Related]
12. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Niijima T; Aso Y; Araki T; Itatani H
Hinyokika Kiyo; 1988 Oct; 34(10):1853-63. PubMed ID: 2977527
[TBL] [Abstract][Full Text] [Related]
13. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
Johansen TE; Ogreid P; Kjellevold K; Blom P
Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Mahler C; Denis L
Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
[TBL] [Abstract][Full Text] [Related]
15. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
[TBL] [Abstract][Full Text] [Related]
16. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
[TBL] [Abstract][Full Text] [Related]
17. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
Furr BJ; Hutchinson FG
Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
[No Abstract] [Full Text] [Related]
19. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
